β-Adrenergic receptors suppress Rap1B prenylation and promote the metastatic phenotype in breast cancer cells

References

• Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell 2011; 144:646-74; PMID:21376230; http://dx.doi.org/10.1016/j.cell.2011.02.013
   PubMed Web of Science ®Google Scholar
• Bos J, De Bruyn K, Enserink J, Kuiperij B, Rangarajan S, Rehmann H, Riedl J, De Rooij J, Van Mansfeld F, Zwartkruis F. The role of rap 1 in integrin-mediated cell adhesion. Biochem Soc Trans 2003; 31:83-6; PMID:12546659; http://dx.doi.org/10.1042/BST0310083
   PubMed Web of Science ®Google Scholar
• Knox A, Brown N. Rap1 GTPase regulation of adherens junction positioning and cell adhesion. Science 2002; 295:1285-8; PMID:11847339; http://dx.doi.org/10.1126/science.1067549
   PubMed Web of Science ®Google Scholar
• Price L, Hajdo-Milasinovic A, Zhao J, Zwartkruis F, Collard J, Bos J. Rap1 regulates E-cadherin-mediated cell-cell adhesion. J Biol Chem 2004; 279:35127-32; PMID:15166221; http://dx.doi.org/10.1074/jbc.M404917200
   PubMed Web of Science ®Google Scholar
• Williams C. The polybasic region of ras and rho family small GTPases: A regulator of protein interactions and membrane association and a site of nuclear localization signal sequences. Cell Signal 2003; 15:1071-80; PMID:14575862; http://dx.doi.org/10.1016/S0898-6568(03)00098-6
   PubMed Web of Science ®Google Scholar
• Ntantie E, Gonyo P, Lorimer EL, Hauser AD, Schuld N, McAllister D, Kalyanaraman B, Dwinell MB, Auchampach JA, Williams CL. An adenosine-mediated signaling pathway suppresses prenylation of the GTPase Rap1B and promotes cell scattering. Sci Signal 2013; 6:ra39; PMID:23716716; http://dx.doi.org/10.1126/scisignal.2003374
   PubMed Web of Science ®Google Scholar
• Cekic C, Sag D, Li Y, Theodorescu D, Strieter RM, Linden J. Adenosine A2B receptor blockade slows growth of bladder and breast tumors. J Immunol 2012; 188:198-205; PMID:22116822; http://dx.doi.org/10.4049/jimmunol.1101845
   PubMed Web of Science ®Google Scholar
• Desmet CJ, Gallenne T, Prieur A, Reyal F, Visser NL, Wittner BS, Smit MA, Geiger TR, Laoukili J, Iskit S. Identification of a pharmacologically tractable fra-1/ADORA2B axis promoting breast cancer metastasis. Proc Natl Acad Sci USA 2013; 110:5139-44; PMID:23483055; http://dx.doi.org/10.1073/pnas.1222085110
   PubMed Web of Science ®Google Scholar
• Fishman P, Bar-Yehuda S, Synowitz M, Powell J, Klotz K, Gessi S, Borea P. Adenosine receptors and cancer. In Wilson CN, Mustafa SJ, Eds.: Adenosine Receptors in Health and Disease. Berlin/Heidelberg: Springer, 2009:399-441.
   Google Scholar
• Li S, Huang S, Peng S. Overexpression of G protein-coupled receptors in cancer cells: Involvement in tumor progression. Int J Oncol 2005; 27:1329; PMID: 16211229
   PubMed Web of Science ®Google Scholar
• Linden J. Adenosine promotes tumor metastasis. Sci Sign 2013; 6:pe20
   PubMed Web of Science ®Google Scholar
• Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D, Dwyer KM, Smyth MJ. Anti-CD73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci USA 2010; 107:1547-52; PMID:20080644; http://dx.doi.org/10.1073/pnas.0908801107
   PubMed Web of Science ®Google Scholar
• Riksen NP, Smits P, Rongen GA. The cardiovascular effects of methylxanthines. Handb Exp Pharmacol 2011; (200):413-37; PMID:20859806; http://dx.doi.org/10.1007/978-3-642-13443-2_16
   PubMedGoogle Scholar
• Campbell JP, Karolak MR, Ma Y, Perrien DS, Masood-Campbell SK, Penner NL, Munoz SA, Zijlstra A, Yang X, Sterling JA. Stimulation of host bone marrow stromal cells by sympathetic nerves promotes breast cancer bone metastasis in mice. PLoS biology 2012; 10:e1001363; PMID:22815651; http://dx.doi.org/10.1371/journal.pbio.1001363
   PubMedGoogle Scholar
• Cole SW, Sood AK. Molecular pathways: Beta-adrenergic signaling in cancer. Clin Cancer Res 2012; 18:1201-6; PMID:22186256; http://dx.doi.org/10.1158/1078-0432.CCR-11-0641
   PubMed Web of Science ®Google Scholar
• Drell IV T, Joseph J, Lang K, Niggemann B, Zaenker K, Entschladen F. Effects of neurotransmitters on the chemokinesis and chemotaxis of MDA-MB-468 human breast carcinoma cells. Breast Cancer Res Treat 2003; 80:63-70; PMID:12889599; http://dx.doi.org/10.1023/A:1024491219366
   PubMed Web of Science ®Google Scholar
• Entschladen F, Drell I, Theodore L, Lang K, Joseph J, Zaenker KS. Neurotransmitters and chemokines regulate tumor cell migration: Potential for a new pharmacological approach to inhibit invasion and metastasis development. Curr Pharm Des 2005; 11:403-11; PMID:15723634; http://dx.doi.org/10.2174/1381612053382197
   PubMed Web of Science ®Google Scholar
• Lang K, Drell TL, Lindecke A, Niggemann B, Kaltschmidt C, Zaenker KS, Entschladen F. Induction of a metastatogenic tumor cell type by neurotransmitters and its pharmacological inhibition by established drugs. Int J Cancer 2004; 112:231-8; PMID:15352035; http://dx.doi.org/10.1002/ijc.20410
   PubMed Web of Science ®Google Scholar
• Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, Arevalo JM, Morizono K, Karanikolas BD, Wu L. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 2010; 70:7042-52; PMID:20823155; http://dx.doi.org/10.1158/0008-5472.CAN-10-0522
   PubMed Web of Science ®Google Scholar
• Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K. Beta blockers and breast cancer mortality: A population-based study. J Clin Oncol 2011; 29:2635-44; PMID:21632503; http://dx.doi.org/10.1200/JCO.2010.33.5422
   PubMed Web of Science ®Google Scholar
• Barron TI, Sharp L, Visvanathan K. Beta-adrenergic blocking drugs in breast cancer: A perspective review. Ther Adv Med Oncol 2012; 4:113-25; PMID:22590485; http://dx.doi.org/10.1177/1758834012439738
   PubMed Web of Science ®Google Scholar
• Benish M, Bartal I, Goldfarb Y, Levi B, Avraham R, Raz A, Ben-Eliyahu S. Perioperative use of beta-blockers and COX-2 inhibitors may improve immune competence and reduce the risk of tumor metastasis. Ann Surg Oncol 2008; 15:2042-52; PMID:18398660; http://dx.doi.org/10.1245/s10434-008-9890-5
   PubMed Web of Science ®Google Scholar
• Botteri E, Munzone E, Rotmensz N, Cipolla C, De Giorgi V, Santillo B, Zanelotti A, Adamoli L, Colleoni M, Viale G. Therapeutic effect of β-blockers in triple-negative breast cancer postmenopausal women. Breast Cancer Res Treat 2013; 140:567-75; PMID:23912960; http://dx.doi.org/10.1007/s10549-013-2654-3
   PubMed Web of Science ®Google Scholar
• Ganz PA, Cole SW. Expanding our therapeutic options: Beta blockers for breast cancer? J Clin Oncol 2011; 29:2612-6; PMID:21632500; http://dx.doi.org/10.1200/JCO.2011.35.8820
   PubMed Web of Science ®Google Scholar
• Melhem-Bertrandt A, Chavez-MacGregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo A. Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 2011; 29:2645-52; PMID:21632501; http://dx.doi.org/10.1200/JCO.2010.33.4441
   PubMed Web of Science ®Google Scholar
• Powe DG, Voss MJ, Zänker KS, Habashy HO, Green AR, Ellis IO, Entschladen F. Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 2010; 1:628; PMID:21317458
   PubMed Web of Science ®Google Scholar
• Powe DG, Entschladen F. Targeted therapies: Using β-blockers to inhibit breast cancer progression. Nat Rev Clin Oncol 2011; 8:511-2; PMID:21808268; http://dx.doi.org/10.1038/nrclinonc.2011.123
   PubMed Web of Science ®Google Scholar
• Powe D, Voss M, Habashy H, Zänker K, Green A, Ellis I, Entschladen F. Alpha-and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: An immunohistochemical study. Breast Cancer Res Treat 2011; 130:457-63; PMID:21298476; http://dx.doi.org/10.1007/s10549-011-1371-z
   PubMed Web of Science ®Google Scholar
• Tang J, Li Z, Lu L, Cho CH. Β-adrenergic system, a backstage manipulator regulating tumour progression and drug target in cancer therapy. Semin Cancer Biol 2013; 23:533-42; PMID:24012659; http://dx.doi.org/10.1016/j.semcancer.2013.08.009
   PubMed Web of Science ®Google Scholar
• National Institute of Health; Columbia University. Study of propranolol in newly diagnosed breast cancer patients undergoing neoadjuvant chemotherapy. In: Clinicaltrials.gov ; Internet. Bethesda (MD): National Library of Medicine (US); updated 2014 July 10- cited 2014 Dec 11. Available from: http://clinicaltrials.gov/ct2/show/NCT01847001?term=beta-adrenergic+and+cancer&rank=20 NLM Identifier: NCT01847001
   Google Scholar
• National Institute of Health. Perioperative administration of cox 2 inhibitors and B-blockers to women undergoing breast cancer surgery In: Clinicaltrials.gov ; Internet. Bethesda (MD): National Library of Medicine (US).; updated 2014 June 27; cited 2014 Dec 11. Available from: http://clinicaltrials.gov/ct2/show/NCT00502684?term=beta-adrenergic+and+cancer&rank=3 NLM Identifier: NCT00502684
   Google Scholar
• Ribeiro-Neto FA, Mattera R, Hildebrandt JD, Codina J, Field JB, Birnbaumer L, Sekura RD. ADP-ribosylation of membrane components by pertussis and cholera toxin. Methods Enzymol 1985; 109:566-72; PMID:2859516; http://dx.doi.org/10.1016/0076-6879(85)09115-7
   PubMed Web of Science ®Google Scholar
• Eckle T, Krahn T, Grenz A, Kohler D, Mittelbronn M, Ledent C, Jacobson MA, Osswald H, Thompson LF, Unertl K, et al. Cardioprotection by ecto-5′-nucleotidase (CD73) and A2B adenosine receptors. Circulation 2007; 115:1581-90; PMID:17353435; http://dx.doi.org/10.1161/CIRCULATIONAHA.106.669697
   PubMed Web of Science ®Google Scholar
• Hidaka H, Kobayashi R. Pharmacology of protein kinase inhibitors. Annu Rev Pharmacol Toxicol 1992; 32:377-97; PMID:1605572; http://dx.doi.org/10.1146/annurev.pa.32.040192.002113
   PubMed Web of Science ®Google Scholar
• Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M. Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 2006; 12:939-44; PMID:16862152; http://dx.doi.org/10.1038/nm1447
   PubMed Web of Science ®Google Scholar
• Palm D, Lang K, Niggemann B, Drell TL, Masur K, Zaenker KS, Entschladen F. The norepinephrine-driven metastasis development of PC-3 human prostate cancer cells in BALB/c nude mice is inhibited by β-blockers. Int J Cancer 2006; 118:2744-9; http://dx.doi.org/10.1002/ijc.21723
   PubMed Web of Science ®Google Scholar
• Zhang D, Ma QY, Hu HT, Zhang M. Beta2-adrenergic antagonists suppress pancreatic cancer cell invasion by inhibiting CREB, NFkappaB and AP-1. Cancer Biol Ther 2010; 10:19-29; PMID:20424515; http://dx.doi.org/10.4161/cbt.10.1.11944
   PubMed Web of Science ®Google Scholar
• Guo K, Ma Q, Wang L, Hu H, Li J, Zhang D, Zhang M. Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol Rep 2009; 22:825; PMID:19724861
   PubMed Web of Science ®Google Scholar
• Masur K, Niggemann B, Zanker KS, Entschladen F. Norepinephrine-induced migration of SW 480 colon carcinoma cells is inhibited by β-blockers. Cancer Res 2001; 61:2866-9; PMID:11306460
   PubMed Web of Science ®Google Scholar
• Glasner A, Avraham R, Rosenne E, Benish M, Zmora O, Shemer S, Meiboom H, Ben-Eliyahu S. Improving survival rates in two models of spontaneous postoperative metastasis in mice by combined administration of a β-adrenergic antagonist and a cyclooxygenase-2 inhibitor. J Immunol 2010; 184:2449-57; PMID:20124103; http://dx.doi.org/10.4049/jimmunol.0903301
   PubMed Web of Science ®Google Scholar
• Lamkin DM, Sloan EK, Patel AJ, Chiang BS, Pimentel MA, Ma JC, Arevalo JM, Morizono K, Cole SW. Chronic stress enhances progression of acute lymphoblastic leukemia via β-adrenergic signaling. Brain Behav Immun 2012; 26:635-41; PMID:22306453; http://dx.doi.org/10.1016/j.bbi.2012.01.013
   PubMed Web of Science ®Google Scholar
• Avraham R, Benish M, Inbar S, Bartal I, Rosenne E, Ben-Eliyahu S. Synergism between immunostimulation and prevention of surgery-induced immune suppression: An approach to reduce post-operative tumor progression. Brain Behav Immun 2010; 24:952-8; PMID:20362661; http://dx.doi.org/10.1016/j.bbi.2010.03.010
   PubMed Web of Science ®Google Scholar
• Melamed R, Rosenne E, Shakhar K, Schwartz Y, Abudarham N, Ben-Eliyahu S. Marginating pulmonary-NK activity and resistance to experimental tumor metastasis: Suppression by surgery and the prophylactic use of a β-adrenergic antagonist and a prostaglandin synthesis inhibitor. Brain Behav Immun 2005; 19:114-26; PMID:15664784; http://dx.doi.org/10.1016/j.bbi.2004.07.004
   PubMed Web of Science ®Google Scholar
• Yamaguchi K, Takagi Y, Aoki S, Futamura M, Saji S. Significant detection of circulating cancer cells in the blood by reverse transcriptase-polymerase chain reaction during colorectal cancer resection. Ann Surg 2000; 232:58-65; PMID:10862196; http://dx.doi.org/10.1097/00000658-200007000-00009
   PubMed Web of Science ®Google Scholar
• Shakhar G, Ben-Eliyahu S. Potential prophylactic measures against postoperative immunosuppression: Could they reduce recurrence rates in oncological patients? Ann Surg Oncol 2003; 10:972-92; PMID:14527919; http://dx.doi.org/10.1245/ASO.2003.02.007
   PubMed Web of Science ®Google Scholar
• Strassheim D, Shafer SH, Phelps SH, Williams CL. Small cell lung carcinoma exhibits greater phospholipase C-beta1 expression and edelfosine resistance compared with non-small cell lung carcinoma. Cancer Res 2000; 60:2730-6; PMID:10825148
   PubMed Web of Science ®Google Scholar